Analysis Of Saraca Asoca (ROXB.) Wild. Activity In Dyslipidemia And Obesity Through Protein Docking And Network Drug Discovery

Abstract

In this generation, the two most prevalent lifestyle disorders are obesity and dyslipidemia. The prevalence of both conditions has been rising in recent decades, beginning around age five. High calorie diets are one of the primary reasons of this. Modern drugs used to treat both conditions have a number of adverse effects, including numbness, insomnia, and sensory distortion. Even if surgery is used to treat both conditions, the likelihood of experiencing these side effects is assured. In order to cure various ailments, plant-based therapy is the preferred option. In Indian traditional medicine, the plant Saraca asoca (Roxb.) Wild is used to treat both dyslipidemia and obesity.Therefore, using network pharmacology and molecular docking analysis, this study aimed to assess the effects of Saracca asoca phytochemicals on the disease targets of obesity and dyslipidemia. In dyslipidemia, there were nine phytochemicals, and in obesity, there were eight, although in both conditions, the total targets were thirty and thirty, respectively. In both diseases, quercetin was the prevalent phytochemical. While linoleic acid and apigenin were beneficial for dyslipidemia, epicatechin and oleic acid were proven to be effective for obesity.The molecular docking analysis exhibited the action of quercetin in both the conditions through CYP1A1 and AKR1C3 in dyslipidemia and obesity respectively. Further evaluation of Saraca asoca in pre-clinical and clinical trials will reveal its safety and efficacy for a further more step in drug discovery.